Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01604928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: YM178
DRUG: tolterodine
DRUG: Placebo

Sponsor

Astellas Pharma Europe B.V.